ArticleBMC psychiatry2025
Exploring gut microbiota profile induced by antipsychotics in schizophrenic patients: insights from an Eastern European pilot study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut Microbiota in Schizophrenia: Taxonomic Shifts, Beta- Diversity Alterations, and Biomarker Potential: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Anti-psychotic therapeutics modify gut microbial metabolism and modulate susceptibility to gastrointestinal infection in mice.bioRxiv : the preprint server for biology · 2026Article
- Gut Microbiome Dysregulation Across Schizophrenia Spectrum Disorders: Bacteria-, Fungi- and Virome-Level Alterations with Molecular and Immunological Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia (SCZ) is an intricate multi-systemic mental illness which has been linked to alterations of the gastrointestinal (GI) microbiota via the bidirectional network known as the gut-brain axis (GBA). However, the specific microbial signatures characterizing SCZ remain unclear.
methodsWe analyzed the gut microbiome composition of 57 Romanian adults, 30 SCZ, and 27 healthy controls (HCs), using amplicon sequencing on the V3-V4 region of the 16S rRNA gene isolated from stool samples. DNA was extracted with an optimized enzymatic and mechanical lysis protocol. Sequence profiling was performed using DADA2. Counts were variance‑stabilized (DESeq2 VST) for Bray–Curtis and weighted UniFrac distance calculation, principal coordinate analysis (PCoA), and permutational multivariate analysis of variance (PERMANOVA). To account for data compositionality, counts were also centered log‑ratio (CLR)–transformed for principal component analysis (PCA) and supervised sparse partial least square linear discriminant analysis (sPLS‑DA). Differential abundance was tested using Wilcoxon rank‑sum (false discovery rate - FDR corrected) and linear discriminant analysis (LDA) effect size (LEfSe) (LDA > 4, FDR < 0.01).
resultsSCZ patients exhibited decreased Bifidobacterium (p = 0.0187), Blautia (p < 0.001), and Eubacterium (p = 0.00120) abundances compared to HCs. Additionally, SCZ patients showed higher Faith’s phylogenetic diversity both before (p = 0.049) and after rarefaction (p = 0.0022), while Shannon and Simpson indices were not significantly different between the two study groups. PCoA on Bray-Curtis and weighted UniFrac distances revealed clear SCZ-HC separation, with unadjusted PERMANOVA attributing 13–15% of variance to SCZ status alone (p = 0.001). After adjusting for smoking, diet, lifestyle, metabolic and comorbidity covariates, SCZ status remained the only significant term which contributed to variance in microbiome composition (R2 ~ 4.4%, p = 0.001). Within the SCZ group, only risperidone use (not age, sex, body mass index - BMI, glycaemia, lipids, or other medication use) was significantly associated with community structure (p < 0.01). PCA and sPLS-DA revealed that the principal drivers for group separation after taking into account the compositional nature of data were Erysipelotrichaceae UCG-003 and Anaerostipes in HCs and Holdemanella in SCZ (all p < 0.0001).
conclusionsOur integrative analyses provide evidence of gut microbiome alterations in SCZ and reveal that risperidone use modulates community structure, underscoring the need to consider the GI effects of antipsychotics when choosing appropriate regimens for patients, while at the same time highlight the GBA as a promising target for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.